Literature DB >> 17725340

Design, synthesis, and characterization of a dual modality positron emission tomography and fluorescence imaging agent for monoclonal antibody tumor-targeted imaging.

Heng Xu1, Kwamena Baidoo, Andrew J Gunn, C Andrew Boswell, Diane E Milenic, Peter L Choyke, Martin W Brechbiel.   

Abstract

A novel lysine-based trifunctional chelate 3 was designed, synthesized, and characterized and bears both a chelating moiety (CHX-A' ') for sequestering radiometals (86Y or 111In) and the near-infrared dye Cy5.5 for dual modality PET (or SPECT) and fluorescence imaging, respectively. Successful conjugation of 3 to the monoclonal antibody trastuzumab (Herceptin) was achieved by efficient thiol-maleimide chemistry, thereby yielding immunoconjugate 2. Analysis of 2 by flow cytometry and competitive binding assay demonstrates that immunoconjugate 2 binds to SKOV3 tumor cells comparably to native trastuzumab and, thus, may be used as a tumor-targeted monoclonal antibody probe for multimodality imaging.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17725340      PMCID: PMC2366096          DOI: 10.1021/jm070657w

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  17 in total

1.  Tissue sulfhydryl groups.

Authors:  G L ELLMAN
Journal:  Arch Biochem Biophys       Date:  1959-05       Impact factor: 4.013

2.  Targeting of HER2 antigen for the treatment of disseminated peritoneal disease.

Authors:  Diane E Milenic; Kayhan Garmestani; Erik D Brady; Paul S Albert; Dangshe Ma; Alia Abdulla; Martin W Brechbiel
Journal:  Clin Cancer Res       Date:  2004-12-01       Impact factor: 12.531

Review 3.  Molecular imaging in the clinical arena.

Authors:  Farouc A Jaffer; Ralph Weissleder
Journal:  JAMA       Date:  2005-02-16       Impact factor: 56.272

4.  Validation of a novel CHX-A'' derivative suitable for peptide conjugation: small animal PET/CT imaging using yttrium-86-CHX-A''-octreotide.

Authors:  Thomas Clifford; C Andrew Boswell; Grainne B Biddlecombe; Jason S Lewis; Martin W Brechbiel
Journal:  J Med Chem       Date:  2006-07-13       Impact factor: 7.446

Review 5.  PET/CT: form and function.

Authors:  Todd M Blodgett; Carolyn C Meltzer; David W Townsend
Journal:  Radiology       Date:  2007-02       Impact factor: 11.105

6.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

7.  Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.

Authors:  T K Nikula; M R McDevitt; R D Finn; C Wu; R W Kozak; K Garmestani; M W Brechbiel; M J Curcio; C G Pippin; L Tiffany-Jones; M W Geerlings; C Apostolidis; R Molinet; M W Geerlings; O A Gansow; D A Scheinberg
Journal:  J Nucl Med       Date:  1999-01       Impact factor: 10.057

8.  The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression.

Authors:  F Xu; Y Yu; X F Le; C Boyer; G B Mills; R C Bast
Journal:  Clin Cancer Res       Date:  1999-11       Impact factor: 12.531

9.  Fluorescently detectable magnetic resonance imaging agents.

Authors:  M M Hüber; A B Staubli; K Kustedjo; M H Gray; J Shih; S E Fraser; R E Jacobs; T J Meade
Journal:  Bioconjug Chem       Date:  1998 Mar-Apr       Impact factor: 4.774

10.  Design and synthesis of a bimodal target-specific contrast agent for angiogenesis.

Authors:  Anouk Dirksen; Sander Langereis; Bas F M de Waal; Marcel H P van Genderen; E W Meijer; Quido G de Lussanet; Tilman M Hackeng
Journal:  Org Lett       Date:  2004-12-23       Impact factor: 6.005

View more
  27 in total

1.  Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials.

Authors:  Diane E Milenic; Karen J Wong; Kwamena E Baidoo; Tapan K Nayak; Celeste A S Regino; Kayhan Garmestani; Martin W Brechbiel
Journal:  MAbs       Date:  2010-09-01       Impact factor: 5.857

Review 2.  Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease.

Authors:  Thaddeus J Wadas; Edward H Wong; Gary R Weisman; Carolyn J Anderson
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

3.  Improved speciation characteristics of PEGylated indocyanine green-labeled Panitumumab: revisiting the solution and spectroscopic properties of a near-infrared emitting anti-HER1 antibody for optical imaging of cancer.

Authors:  Aaron Joseph L Villaraza; Diane E Milenic; Martin W Brechbiel
Journal:  Bioconjug Chem       Date:  2010-11-12       Impact factor: 4.774

4.  Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications.

Authors:  Diane E Milenic; Karen J Wong; Kwamena E Baidoo; Geoffrey L Ray; Kayhan Garmestani; Mark Williams; Martin W Brechbiel
Journal:  Cancer Biother Radiopharm       Date:  2008-10       Impact factor: 3.099

Review 5.  Multimodality imaging probes: design and challenges.

Authors:  Angelique Louie
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

6.  In Vitro and In Vivo Pre-Clinical Analysis of a F(ab')(2) Fragment of Panitumumab for Molecular Imaging and Therapy of HER1 Positive Cancers.

Authors:  Karen J Wong; Kwamena E Baidoo; Tapan K Nayak; Kayhan Garmestani; Martin W Brechbiel; Diane E Milenic
Journal:  EJNMMI Res       Date:  2011-06-07       Impact factor: 3.138

7.  Synthesis of a Fluorescently Labeled 68Ga-DOTA-TOC Analog for Somatostatin Receptor Targeting.

Authors:  Sukhen C Ghosh; Servando Hernandez Vargas; Melissa Rodriguez; Susanne Kossatz; Julie Voss; Kendra S Carmon; Thomas Reiner; Agnes Schonbrunn; Ali Azhdarinia
Journal:  ACS Med Chem Lett       Date:  2017-06-06       Impact factor: 4.345

Review 8.  Nuclear and Optical Bimodal Imaging Probes Using Sequential Assembly: A Perspective.

Authors:  Shin Hye Ahn; Eszter Boros
Journal:  Cancer Biother Radiopharm       Date:  2018-07-13       Impact factor: 3.099

9.  Exploration of a F(ab')2 Fragment as the Targeting Agent of α-Radiation Therapy: A Comparison of the Therapeutic Benefit of Intraperitoneal and Intravenous Administered Radioimmunotherapy.

Authors:  Diane E Milenic; Young-Seung Kim; Kwamena E Baidoo; Karen J Wong; Rachel Barkley; Jose Delgado; Martin W Brechbiel
Journal:  Cancer Biother Radiopharm       Date:  2018-06       Impact factor: 3.099

10.  A novel bifunctional maleimido CHX-A'' chelator for conjugation to thiol-containing biomolecules.

Authors:  Heng Xu; Kwamena E Baidoo; Karen J Wong; Martin W Brechbiel
Journal:  Bioorg Med Chem Lett       Date:  2008-03-10       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.